Periodontal Disease in the COVID-19 Era: Potential Reservoir and Increased Risk for SARS–CoV-2

Martinna Bertolini¹, Afroditi Pita¹, Sungeun Koo¹, Anibal Cardenas¹, Archana Meethil¹

¹Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, University of Connecticut, Farmington, CT, USA.

Author to whom correspondence should be addressed: Martinna Bertolini, Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, University of Connecticut, 263 Farmington Ave, Farmington, CT, USA. Phone: +1 860 970 6391. E-mail: martinnabertolini@gmail.com

Academic Editor: Yuri Wanderley Cavalcanti

Received: 16 June 2020 / Review: 28 June 2020 / Accepted: 06 July 2020


Abstract
Since December 2019, an outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and is now becoming a global Pandemic, with over 10.5 million cases worldwide. Angiotensin-converting enzyme-2 (ACE-2) has been considered the main receptor for the SARS-CoV-2 entry into human cells, and they are known to be present not only in lungs (therefore the common viral pneumonia) but also in nasopharyngeal mucosa, salivary cells and oral epithelial cells. Moreover, there seems to be recent evidence showing that the crevicular fluid on the periodontal pockets of patients presenting periodontitis could harbor SARS-CoV-2 and act as a potential reservoir for increased viral load in the oral cavity of COVID-positive patients. Additionally, sites with active periodontal disease might contribute for virus binding and tissue infection due to elevated expression of furin and cathepsin L proteases, which play a major role in enabling the SARS-CoV-2 to bind ACE-2 receptors and facilitating endosomal fusion in the host cells. Taken together this news and views article highlight possible virus reservoirs in COVID-positive patients, as well as increased risk for infection in patients with active periodontal disease, further proposing potential targets for antiviral intervention on SARS-CoV-2 infection.

Keywords: Coronavirus Infections; SARS Virus; Periodontics; Periodontal Diseases.
Introduction

In December of 2019, series of pneumonia cases were reported in China [1] associated with a novel coronavirus, which has been identified as "Severe Acute Respiratory Syndrome Coronavirus 2" (SARS-CoV-2), that is phylogenetically related to the class of viruses that cause acute respiratory syndrome, including SARS-CoV and MERS-CoV. Later, in January 2020, the disease was named "COVID-19" ("COVI" - coronavirus, "D" - disease, and 19 represents 2019 when the virus was first identified in China).

Current epidemiologic data from WHO [1] indicate that person-to-person contact led to a total of more than 10.5 million cases in at least 21 countries by January 2020 [2]. And currently, Brazil accounts for almost 11% of all COVID-positive cases worldwide. While investigations are still underway worldwide to better understand transmission dynamics and the spectrum of clinical illness, new guidelines are proposed daily with measures on how to better manage possible infected patients and reduce spreading.

As we enter the second quarter of the COVID-19 pandemic, with dental practices reopening for patient care, two important questions were recently raised in the periodontal research community: 1) Are periodontal pockets a potential reservoir for SARS-CoV-2? [3]; 2) Can periodontal disease increase the risk of COVID-19? [4]. We think these two questions are worth it the discussion, as they might help to re-shape the future guidelines for periodontal therapy on periodontitis patients positive for COVID-19.

Periodontal Disease and Viruses

Periodontal disease is a chronic multifactorial inflammatory disease characterized by progressive destruction of the tooth-supporting apparatus. Though the bacterial biofilm accumulation and maturation initiates gingival inflammation, progression of periodontal disease occurs consequent to the host response and dysbiotic changes in the microbiome. Dysbiosis may be modulated by inflammatory and tissue breakdown products, which selectively enrich certain bacterial species and by anti-inflammatory products released at the site of inflammation [5].

Since the mid-1990s, viruses have been described as pathogens related to periodontal disease, with Epstein-Barr virus type 1 (EBV-1) being detected in 43% of periodontal sites and in only 18% of healthy sites [6]. Later, Herpes simplex virus and Human Cytomegalovirus have been described as positive in periodontal pockets of 26–78% and 42–58%, respectively, of patients with periodontal disease, showing different virus families be found in unique rates across the population [7].

Further corroborating this, a recent shot-gun DNA sequencing study of subgingival plaque collected from healthy and periodontal disease patients showed that even though bacteria were the most abundant component of the subgingival plaque, with over 95% of the reads, viruses were also present in these complex communities associated with bacterial biofilm complexes [8].

Are Periodontal Pockets a Potential Reservoir for SARS-CoV-2?

This hypothesis was raised by Badran et al. [3], based on the idea that periodontal pockets could be a favorable environment for virus replication and survival and could, therefore, be an additional focus of infection in COVID-positive patients.

The initial viral infection of periodontal tissues could start either from direct infection of coming from the mouth or from cells basement membrane by bloodstream or infected immune cells [9]. The continuous inflammatory response present in affected sites of periodontal disease could bring mononuclear cells infected
by SARS-CoV-2 [10]. Thus, it is reasonable to think that the crevicular fluid on the periodontal pocket could harbor virus arriving from infected mononuclear cells and further mix with patient’s saliva.

Angiotensin-converting enzyme-2 (ACE-2) has been considered the main receptor for the SARS-CoV-2 entry into human cells, and they are present not only in lungs (therefore the common viral pneumonia), but also in nasopharyngeal mucosa, salivary gland and oral epithelial cells [11]. This results in high viral load in the oral cavity (saliva and crevicular fluid), which has been tackled in dental practices by antimicrobial pre-rinises composed by povidone-iodine has been showing promising results in terms of viral killing [12].

Although this has not been experimentally tested yet, it seems plausible that periodontal pockets need to be tested as potential reservoirs for SARS-CoV-2, as they present interactions with the oral cavity and bloodstream via capillary complexes. This hypothesis could be further extrapolated to the peri-implant environment, as increased inflammation is also found around implants and increased EBV prevalence has also been described in peri-implant sites when compared to healthy sites [13].

**Does Periodontal Disease Increase the Risk of COVID 19?**

This hypothesis was raised by Balaji et al. [4], based on the fact that the patients presenting periodontal disease exhibit high levels of osteopontin in the gingival crevicular fluid from sites with periodontal destruction [14], and its downstream products play a major role in enabling the SARS-CoV-2 to infect the host cells.

Osteopontin is a noncollagenous, calcium-binding, glycosylated phosphoprotein, commonly found in the mineralized phase of bone matrix, which is mainly synthesized by pre-osteoblasts, osteoblasts and osteoclastic cells and has been shown to be elevated in periodontitis [15]. High osteopontin levels induces NF-κB activation, which then increases furin expression [16]. An inflammatory response (interleukin - IL-6) via gingival fibroblasts will also lead to increased expression of Cathepsin L, a cysteine protease [17].

Both, furin and cathepsin L play a major role in enabling the SARS-CoV-2 to infect the host cells by cleaving S glycoprotein of the SARS-CoV-2 into S1 and S2 subunits by furin, allowing S1 subunit attaches itself to the ACE2 receptors present in the host cells. Finally, endosomal fusion is mediated by cathepsin B/L, allowing cell fusion and infection [18].

Unravelling which cellular factors are used by SARS-CoV-2 for cell entry might provide insights into viral transmission and reveal therapeutic targets. Recently, Hoffmann et al. [18] demonstrated a protease inhibitor (TMPRSS2, approved for clinical use) was able to block the virus entry on the host cells. Their results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.

**Final Considerations**

In order to tackle the COVID-19 pandemic efficiently, it is crucial to reduce the spread of the infection by not only carrying out extraordinary prevention and safety measures, but also identifying possible virus reservoirs in COVID-positive patients, as well as identify potential targets for antiviral intervention on SARS-CoV-2 infection.

This new and views of two recent publications in the periodontal field highlight that periodontal therapy could be considered a parameter of care in the global clinical management of COVID-positive patients, aiming the reduction of viral reservoir in the periodontal pockets. Active periodontal treatment could decrease the expression of furin and cathepsin L, reducing the ability of SARS-CoV-2 to infect the host cells.
Conflicts of Interest

The authors declare no conflicts of interest.

References


